Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
24.81
Dollar change
+1.15
Percentage change
4.86
%
IndexRUT P/E- EPS (ttm)-6.07 Insider Own14.63% Shs Outstand30.43M Perf Week-0.60%
Market Cap754.93M Forward P/E- EPS next Y-6.40 Insider Trans5.15% Shs Float25.98M Perf Month11.71%
Income-165.66M PEG- EPS next Q-1.55 Inst Own98.19% Short Float25.84% Perf Quarter-30.26%
Sales57.17M P/S13.21 EPS this Y1.24% Inst Trans18.76% Short Ratio15.43 Perf Half Y5.89%
Book/sh2.77 P/B8.95 EPS next Y-6.56% ROA-33.78% Short Interest6.71M Perf Year54.48%
Cash/sh14.14 P/C1.76 EPS next 5Y- ROE-161.81% 52W Range15.78 - 41.31 Perf YTD15.83%
Dividend Est.- P/FCF- EPS past 5Y-19.45% ROI-36.85% 52W High-39.94% Beta-0.13
Dividend TTM- Quick Ratio10.23 Sales past 5Y172.96% Gross Margin95.80% 52W Low57.22% ATR (14)2.01
Dividend Ex-Date- Current Ratio10.23 EPS Y/Y TTM-12.12% Oper. Margin-245.01% RSI (14)52.19 Volatility10.74% 8.11%
Employees117 Debt/Eq4.35 Sales Y/Y TTM282.17% Profit Margin-289.75% Recom1.50 Target Price55.30
Option/ShortYes / Yes LT Debt/Eq4.33 EPS Q/Q19.10% Payout- Rel Volume1.52 Prev Close23.66
Sales Surprise265.83% EPS Surprise30.78% Sales Q/Q804.67% EarningsNov 05 AMC Avg Volume435.07K Price24.81
SMA2011.23% SMA50-9.12% SMA200-10.74% Trades Volume660,214 Change4.86%
Date Action Analyst Rating Change Price Target Change
Dec-02-24Downgrade BTIG Research Buy → Neutral
Jul-22-24Initiated H.C. Wainwright Buy $55
Jul-19-24Upgrade JP Morgan Neutral → Overweight $29 → $69
Apr-16-24Initiated Leerink Partners Outperform $47
Apr-11-24Initiated Wells Fargo Overweight $56
Mar-12-24Upgrade Wedbush Neutral → Outperform $20 → $34
Feb-26-24Initiated BTIG Research Buy $55
Feb-21-24Initiated Stifel Buy $50
Feb-16-24Initiated Piper Sandler Overweight $80
May-22-23Upgrade JP Morgan Underweight → Neutral $31 → $30
Nov-25-24 09:40AM
Nov-08-24 12:00PM
09:35AM
Nov-05-24 05:30PM
04:15PM
04:15PM Loading…
04:15PM
Aug-29-24 09:15AM
Aug-23-24 07:26AM
Aug-14-24 04:11PM
10:05AM
05:00AM
Aug-05-24 09:54PM
05:55PM
04:15PM
Jul-29-24 10:00AM
02:53PM Loading…
Jul-22-24 02:53PM
May-09-24 05:45PM
04:15PM
04:10PM
04:05PM
May-02-24 10:01AM
May-01-24 04:51AM
Apr-24-24 09:00AM
Apr-15-24 02:19PM
Apr-12-24 07:00PM
Apr-09-24 02:40PM
Mar-14-24 12:00PM
09:55AM
Mar-11-24 05:30PM
04:15PM
09:15AM Loading…
Feb-29-24 09:15AM
Feb-28-24 10:00AM
Feb-22-24 04:00AM
Feb-19-24 05:54AM
Jan-31-24 09:15AM
Jan-12-24 03:02PM
Dec-07-23 09:55AM
Nov-27-23 04:15PM
Nov-14-23 09:35AM
Nov-07-23 04:15PM
Nov-04-23 05:41AM
Nov-02-23 04:15PM
Nov-01-23 09:15AM
Oct-11-23 09:15AM
Oct-09-23 08:27AM
08:15AM
08:05AM
08:00AM
Sep-19-23 03:01PM
Sep-18-23 04:15PM
Sep-12-23 09:15AM
Aug-07-23 04:15PM
Jul-31-23 01:34PM
Jul-04-23 06:22AM
May-30-23 04:15PM
May-24-23 06:01AM
May-22-23 01:44AM
May-11-23 05:35PM
04:15PM
May-04-23 09:55AM
May-02-23 09:15AM
Apr-30-23 09:47AM
Apr-27-23 10:02AM
Apr-26-23 10:02AM
Apr-14-23 03:13AM
Apr-06-23 04:15PM
Apr-03-23 07:14AM
Mar-27-23 06:50PM
Mar-01-23 05:45PM
04:05PM
Feb-27-23 04:05PM
Jan-13-23 09:00AM
Jan-05-23 04:05PM
Dec-22-22 09:33AM
Dec-02-22 09:00AM
Nov-21-22 01:56PM
Nov-11-22 05:19AM
Nov-09-22 02:10PM
Nov-08-22 05:55PM
04:05PM
Oct-25-22 06:28AM
Oct-13-22 09:55AM
Oct-06-22 11:02AM
Oct-05-22 11:31AM
09:00AM
Sep-26-22 08:00AM
Sep-19-22 02:02PM
Sep-14-22 06:14AM
Sep-12-22 11:18AM
07:30AM
Sep-02-22 01:41PM
Sep-01-22 09:58AM
Aug-31-22 04:15PM
Aug-10-22 06:28AM
Aug-08-22 05:35PM
04:05PM
Aug-05-22 04:00PM
Jul-08-22 07:22AM
Jun-24-22 06:31AM
Jun-02-22 04:05PM
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RENTON HOLLINGSDirectorNov 29 '24Option Exercise6.9310,00069,30011,950Dec 03 04:35 PM
RENTON HOLLINGSDirectorNov 29 '24Sale25.0010,000250,0001,950Dec 03 04:35 PM
HOLLINGS C RENTONDirectorNov 29 '24Proposed Sale25.0010,000250,000Nov 29 01:29 PM
Lizzul Paul F.Chief Medical OfficerSep 23 '24Option Exercise18.501,50027,75016,898Sep 24 04:18 PM
Lizzul Paul F.Chief Medical OfficerSep 23 '24Sale38.671,50058,00515,398Sep 24 04:18 PM
PAUL F LIZZULOfficerSep 23 '24Proposed Sale38.671,50058,005Sep 23 04:16 PM
Orwin John ADirectorSep 15 '24Option Exercise0.001,30003,335Sep 17 06:45 PM
LOUMEAU ERIC JCHIEF LEGAL OFFICERSep 16 '24Option Exercise14.025,00070,10013,520Sep 17 06:44 PM
LOUMEAU ERIC JCHIEF LEGAL OFFICERSep 14 '24Option Exercise0.006,000010,740Sep 17 06:44 PM
LOUMEAU ERIC JCHIEF LEGAL OFFICERSep 16 '24Sale39.828,720347,2707,020Sep 17 06:44 PM
LOUMEAU ERIC JCHIEF LEGAL OFFICERSep 17 '24Sale38.413,780145,1913,240Sep 17 06:44 PM
Lizzul Paul F.Chief Medical OfficerSep 16 '24Sale38.932,22086,42515,398Sep 17 06:42 PM
MULROY DENNISCHIEF FINANCIAL OFFICERSep 16 '24Option Exercise20.1610,000201,60014,744Sep 17 06:41 PM
MULROY DENNISCHIEF FINANCIAL OFFICERSep 16 '24Sale39.9112,220487,7254,744Sep 17 06:41 PM
ERIC J LOUMEAUOfficerSep 17 '24Proposed Sale38.413,780145,191Sep 17 04:02 PM
DENNIS MULROYOfficerSep 16 '24Proposed Sale40.1310,000401,300Sep 16 04:33 PM
ERIC J LOUMEAUOfficerSep 16 '24Proposed Sale40.136,500260,845Sep 16 04:22 PM
Lizzul Paul F.Chief Medical OfficerAug 14 '24Option Exercise18.502,00037,00013,618Aug 16 04:09 PM
Lizzul Paul F.Chief Medical OfficerAug 14 '24Sale40.002,00080,00011,618Aug 16 04:09 PM
EcoR1 Capital, LLC10% OwnerAug 14 '24Buy36.50273,9729,999,9787,794,996Aug 16 12:04 PM
PAUL F LIZZULOfficerAug 14 '24Proposed Sale40.002,00080,000Aug 14 04:34 PM
Lizzul Paul F.Chief Medical OfficerJul 18 '24Option Exercise18.501,50027,75013,118Jul 19 08:35 PM
Lizzul Paul F.Chief Medical OfficerJul 18 '24Sale35.001,50052,50011,618Jul 19 08:35 PM
RENTON HOLLINGSDirectorJul 15 '24Option Exercise6.9310,00069,30011,950Jul 17 04:45 PM
RENTON HOLLINGSDirectorJul 15 '24Sale30.6410,000306,4221,950Jul 17 04:45 PM
FENTON DENNIS MDirectorJun 21 '24Sale23.171,95045,1821,950Jun 24 05:23 PM
FENTON DENNIS MDirectorJun 15 '24Option Exercise0.003,90003,900Jun 18 08:18 PM
Marquet MagdaDirectorJun 15 '24Option Exercise0.003,90003,900Jun 18 08:17 PM
Schmid John P.DirectorJun 15 '24Option Exercise0.003,90003,900Jun 18 08:17 PM
Ware J. AnthonyDirectorJun 15 '24Option Exercise0.003,90007,500Jun 18 08:16 PM
Orwin John ADirectorJun 15 '24Option Exercise0.002,03502,035Jun 18 08:15 PM
RENTON HOLLINGSDirectorJun 15 '24Option Exercise0.003,90003,900Jun 18 08:15 PM
RENTON HOLLINGSDirectorJun 18 '24Sale23.161,95045,1621,950Jun 18 08:15 PM
Jain RitaDirectorJun 15 '24Option Exercise0.004,53404,534Jun 18 08:14 PM
MULROY DENNISCHIEF FINANCIAL OFFICERMay 22 '24Sale23.721,50035,580964May 24 04:12 PM
Faga DanielCEOMar 22 '24Sale22.78145,9403,325,185752,087Mar 26 08:10 PM
Faga DanielCEOMar 25 '24Sale21.423,00064,268749,087Mar 26 08:10 PM
LOUMEAU ERIC JCHIEF LEGAL OFFICERFeb 16 '24Option Exercise14.025,00070,1008,240Feb 21 05:38 PM
LOUMEAU ERIC JCHIEF LEGAL OFFICERFeb 16 '24Sale25.005,000125,0003,240Feb 21 05:38 PM
MULROY DENNISCHIEF FINANCIAL OFFICERJan 30 '24Sale23.633,06572,425964Feb 01 05:27 PM
Lizzul Paul F.Chief Medical OfficerJan 06 '24Option Exercise0.006,145012,672Jan 09 07:08 PM
Lizzul Paul F.Chief Medical OfficerJan 08 '24Sale21.812,55455,70310,118Jan 09 07:08 PM
LOUMEAU ERIC JChief Legal OfficerJan 06 '24Option Exercise0.005,54505,545Jan 09 07:07 PM
LOUMEAU ERIC JChief Legal OfficerJan 08 '24Sale21.812,30550,2723,240Jan 09 07:07 PM
MULROY DENNISChief Financial OfficerJan 06 '24Option Exercise0.005,24506,209Jan 09 07:06 PM
MULROY DENNISChief Financial OfficerJan 08 '24Sale21.812,18047,5464,029Jan 09 07:06 PM
Faga DanielCEOJan 06 '24Option Exercise0.0017,8500904,893Jan 09 07:05 PM
Faga DanielCEOJan 08 '24Sale21.816,866149,747898,027Jan 09 07:05 PM